- Home
- ATHA vs NCRA Comparison
ATHA vs NCRA Comparison
Compare ATHA & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- NCRA
- Stock Information
- Founded
- ATHA 2011
- NCRA 2002
- Country
- ATHA United States
- NCRA Taiwan
- Employees
- ATHA N/A
- NCRA N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- NCRA Farming/Seeds/Milling
- Sector
- ATHA Health Care
- NCRA Consumer Staples
- Exchange
- ATHA Nasdaq
- NCRA Nasdaq
- Market Cap
- ATHA 21.0M
- NCRA 16.8M
- IPO Year
- ATHA 2020
- NCRA N/A
- Fundamental
- Price
- ATHA $0.30
- NCRA $0.99
- Analyst Decision
- ATHA Buy
- NCRA
- Analyst Count
- ATHA 4
- NCRA 0
- Target Price
- ATHA $11.25
- NCRA N/A
- AVG Volume (30 Days)
- ATHA 206.7K
- NCRA 20.2K
- Earning Date
- ATHA 05-14-2025
- NCRA 05-14-2025
- Dividend Yield
- ATHA N/A
- NCRA N/A
- EPS Growth
- ATHA N/A
- NCRA N/A
- EPS
- ATHA N/A
- NCRA N/A
- Revenue
- ATHA N/A
- NCRA $20,483,694.00
- Revenue This Year
- ATHA N/A
- NCRA N/A
- Revenue Next Year
- ATHA N/A
- NCRA N/A
- P/E Ratio
- ATHA N/A
- NCRA N/A
- Revenue Growth
- ATHA N/A
- NCRA N/A
- 52 Week Low
- ATHA $0.22
- NCRA $0.70
- 52 Week High
- ATHA $3.67
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- ATHA 49.02
- NCRA 54.10
- Support Level
- ATHA $0.22
- NCRA $0.84
- Resistance Level
- ATHA $0.30
- NCRA $1.00
- Average True Range (ATR)
- ATHA 0.03
- NCRA 0.08
- MACD
- ATHA 0.01
- NCRA 0.00
- Stochastic Oscillator
- ATHA 79.22
- NCRA 86.24
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.